NCT07735754Not yet recruiting
A Step Forward for Unraveling the Immune Mechanisms and Tools for Tuberculosis Spectrum Management
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
Tuberculosis (TB) is a significant infectious disease worldwide, with millions of people infected and major impact on mortality and public health. TB-SPECTRUM project will conduct a clinical study to characterize better clinically, microbiologically, and immunologically the spectrum of TB across the different stages of infection, including incipient and asymptomatic/subclinical TB, active disease, and post treatment phases. Passive and active case-finding (ACF) clinical approaches will be implemented, recruiting TB patients through public and private healthcare facilities and targeted community outreach, as well as their close contacts. This approach will allow the study of biomarker profiles associated with infection risk, disease progression and response to treatment. The specific objectives of the study will be: * To unravel immune mechanisms underlying the TB spectrum through a multidisciplinary approach. * To perform a clinical study (passive and ACF) for recruiting patients and their contacts for the enrolment of incipient/subclinical TB forms and the subsequent immune characterization and management. * To characterize host systemic and local immune responses on different TB immune states (with special focus on incipient, subclinical and cured TB) to better understand host-pathogen interactions and the established cellular/humoral immune mechanisms. * To stratify host immunity according to patient's clinical strain characterization and disease severity. * To develop and evaluate innovative tools for better management of all phases of the TB spectrum.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 940 (estimated)
- First submitted
- 24 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Irene Latorre Rueda
- Diseases
- Tuberculosis
- NCT number
- NCT07735754
What you commit to
- Study type: Observational
- Planned participants: 940
- From 1 Sept 2026 to the primary completion date, 30 Sept 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected immunodeficiency (including HIV or immunosuppressive therapy)
Other
- Known or suspected pregnancy
Who the study is looking for
- Age between 5 and 65 years
- Willing and able to provide informed consent (or legal guardian consent) \*GROUP 1: Active pulmonary TB\*
- Bacteriologically confirmed TB
- Pulmonary TB
- Anti-TB treatment ≤ 14 days \*GROUP 2: Close contacts of active pulmonary TB\*
- Close contact with confirmed pulmonary TB case
- Exposure ≥6 hours/day for ≥5 days/week
- Positive TST and/or IGRA
- NOT receiving TB preventive therapy \*GROUP 3: Other respiratory diseases (non-TB)\*
- Diagnosis of ARI (Acute Respiratory Infection) and/or sarcoidosis and/or lung cancer
- Clinical/radiological findings consistent with non-TB disease
- NO clinical suspicion compatible with active TB \*GROUP 4: Healthy uninfected controls\*
- No symptoms suggestive of active TB
- Not known prior exposure to active TB
- Negative TST and/or IGRA
Age in the registry: 5 years to 65 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.